Traders should monitor for potential regulatory filings or closing announcements. The addition of a novel IVL platform positions Stryker to capture share in the fast-growing calcium modification market, which could drive long-term revenue growth in the Peripheral Vascular segment.
Price Chart
Executive Summary
Stryker announced a definitive agreement to acquire Amplitude Vascular Systems, a private developer of next-generation intravascular lithotripsy (IVL) technology for treating calcified peripheral arterial disease. The acquisition strengthens Stryker’s Peripheral Vascular portfolio and advances its strategy in arterial disease treatment, with the deal subject to customary closing conditions.
Key Facts
- Stryker is acquiring Amplitude Vascular Systems (AVS), a privately held company developing a next-generation IVL platform for calcified peripheral arterial disease.
- AVS’ technology uses pulsed CO₂-generated pressure waves via a balloon catheter to fracture calcium and improve luminal gain, enhancing deliverability and treatment efficiency.
- The acquisition expands Stryker’s Peripheral Vascular (PV) portfolio and supports its strategy to build a comprehensive PV platform.
- Transaction is subject to customary closing conditions; both companies will operate independently until closing.
- AVS was founded in 2017 and is backed by BioStar Capital, Cue Growth Partners, and other global investors.
Financial Impact
Undisclosed amount; likely mid- to high-hundreds of millions given strategic fit and technology stage.
Risk Factors
- Regulatory or antitrust delays could push back the close.
- Integration risk if AVS’ technology does not scale as expected.
- Potential for future dilution if financing is required, though none disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272439 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Press Release | $317.40 $275.39 | ▼ −13.24% | ▼ −13.55% | $275.08 (−13.33%) |
Aug 26, 2026 5w ago | Insider Cluster | $329.67 $274.19 | ▼ −16.83% | ▼ −18.03% | $275.08 (−16.56%) |
Aug 20, 2026 6w ago | Insider Cluster | $327.70 $280.13 | ▼ −14.52% | ▼ −14.52% | $275.08 (−16.06%) |
Jul 13, 2026 11w ago | Court Ruling | $331.45 $345.81 | ▲ +4.33% | ▲ +1.15% | $275.08 (−17.01%) |
Jul 9, 2026 12w ago | ANALYST-UPGRADE | $327.11 $337.43 | ▲ +3.15% | ▲ +0.91% | $275.08 (−15.91%) |
Jun 26, 2026 13w ago | 8-K | $332.71 $318.97 | ▼ −4.13% | ▼ −5.39% | $275.08 (−17.32%) |
Jun 17, 2026 15w ago | Court Ruling | $301.14 $331.20 | ▲ +9.98% | ▲ +8.66% | $275.08 (−8.65%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $275.08 (−8.07%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $275.08 (−8.07%) |
Apr 30, 2026 22w ago | Press Release | $293.78 $299.24 | ▼ −1.86% | ▲ +3.41% | $275.08 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access